Theraliv 275, 275 mg 12 pcs

The drug Teraliv 275 is naproxen and has analgesic, antipyretic and anti-inflammatory effects. The mechanism of action is related to non-selective inhibition of cyclooxygenase-1 and -2 (COX-1, COX-2) activity.

Indications

Diseases of the musculoskeletal system:

rheumatic soft tissue damage;
osteoarthritis of peripheral joints and spine, incl. with radicular syndrome;
tenosynovitis;
bursitis.

Pain syndrome of mild or moderate severity:

neuralgia;
ossalgia;
myalgia;
sciatica;
post-traumatic pain syndrome (sprains and bruises), accompanied by inflammation;
headache, migraine;
algodismenorrhea;
toothache.

As part of complex therapy for infectious and inflammatory diseases of the ear, nose and throat with severe pain:

pharyngitis;
tonsillitis;
otitis.

Feverish syndrome with “colds” and infectious diseases.

Theraliv 275 is used for symptomatic therapy (to reduce pain, inflammation and fever) and does not affect the progression of the underlying disease.

Pharmacological effect

The drug Teraliv 275 is naproxen, has analgesic, antipyretic and anti-inflammatory effects. The mechanism of action is associated with non-selective inhibition of the activity of cyclooxygenase-1 and -2 (COX-1, COX-2).

Special instructions

Do not exceed the doses indicated in the instructions. To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used in the shortest possible short course.
If pain and fever persist or become worse, you should consult a doctor.

Patients with bronchial asthma, bleeding disorders, as well as patients with hypersensitivity to other analgesics should consult a doctor before taking Theraliv 275.
Use with caution in patients with liver disease and renal failure.
In chronic alcoholism and other forms of liver cirrhosis, the concentration of unbound naproxen increases, so lower doses are recommended for such patients. After two weeks of using the drug, monitoring of liver function indicators is necessary.
In patients with renal failure, it is necessary to monitor CC. When CC is less than 30 ml/min, the use of naproxen is not recommended.
Theraliv 275 should not be taken together with other anti-inflammatory and painkillers, unless prescribed by a doctor.

Lower doses are also recommended for elderly patients.
Naproxen should be avoided within 48 hours before surgery.
If it is necessary to determine 17-corticosteroids, the drug should be discontinued 48 hours before the study. Similarly, naproxen may affect the determination of 5-hydroxyindoleacetic acid in urine.

Each tablet of Theraliv 275 contains approximately 25 mg of sodium. When limiting salt intake, this must be taken into account.
Impact on the ability to drive vehicles and machinery

Naproxen slows down the reaction rate in patients. This should be taken into account when driving and performing tasks that require increased attention.

Active ingredient

Naproxen

Composition

1 tab.
naproxen sodium
275 mg

Excipients:

microcrystalline cellulose – 55 mg,

povidone K30 – 12.5 mg,

talc – 15.75 mg,

magnesium stearate – 2.63 mg;

film cover:

opadry blue YS-1-4215 – 9 mg:

macrogol 8000,

indigo carmine,

titanium dioxide,

hypromellose.

Contraindications

Hypersensitivity to naproxen or naproxen sodium;
complete or incomplete combination of bronchial asthma, recurrent nasal polyposis or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history);
period after coronary artery bypass surgery;
erosive and ulcerative changes in the mucous membrane of the stomach or duodenum;
active gastrointestinal bleeding;
inflammatory bowel diseases (ulcerative colitis, Crohn’s disease) in the acute phase;
hemophilia and other bleeding disorders and hemostasis disorders;
cerebrovascular bleeding or other bleeding;
decompensated heart failure.
severe liver failure or active liver disease;
severe renal failure (creatinine clearance less than 30 ml/min), progressive kidney disease;
confirmed hyperkalemia;
pregnancy;
breastfeeding period;
children under 15 years of age.
With caution
IHD, cerebrovascular diseases, congestive heart failure, dyslipidemia/hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, impaired renal function (creatinine clearance 30-60 ml/min), history of gastrointestinal ulceration, presence of Helicobacter pylori infection, use in elderly patients, systemic lupus erythematosus or mixed connective tissue diseases (Sharpe’s syndrome), long-term use of NSAIDs, frequent alcohol consumption, severe somatic illnesses, concomitant therapy with the following drugs: anticoagulants (for example, warfarin), antiplatelet agents (for example, acetylsalicylic acid, clopidogrel), oral glucocorticoids (for example, prednisolone), selective serotonin reuptake inhibitors (for example, citalopram, fluoxetine, paroxetine, sertraline).

Side Effects

Adverse effects that may occur during treatment with naproxen are classified according to the following frequencies: very common (> 1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (< 1/10000), frequency unknown (cannot be determined from available data).

Interaction

When treating with anticoagulants, be aware that naproxen may prolong bleeding time. Theraliv 275 should not be used simultaneously with acetylsalicylic acid or other NSAIDs, including selective COX-2 inhibitors (increased risk of side effects).

Patients concomitantly receiving hydantoins, anticoagulants, or other drugs that are significantly bound to plasma proteins should be monitored for signs of potentiation of action or overdose of these drugs.
Theraliv 275 may reduce the antihypertensive effect of propranolol and other beta-blockers, and may also increase the risk of renal failure associated with the use of ACE inhibitors.

NSAIDs may reduce the diuretic effect of diuretics. Naproxen inhibits the natriuretic effect of furosemide. Diuretics may increase the risk of NSAID nephrotoxicity.

Inhibition of renal clearance of lithium leads to an increase in plasma lithium concentrations. Taking probenecid increases the plasma concentration of naproxen. Cyclosporine increases the risk of developing renal failure.

Naproxen slows down the excretion of methotrexate, phenytoin, and sulfonamides, increasing the risk of developing their toxic effects.

Overdose

Symptoms: a significant overdose of naproxen may be characterized by drowsiness, dyspeptic disorders (heartburn, nausea, vomiting, abdominal pain), weakness, tinnitus, irritability, and in severe cases, hematemesis, melena, impaired consciousness, convulsions and renal failure.

Treatment: a patient who has accidentally or intentionally taken a large amount of Theraliv 275 must rinse the stomach, take activated charcoal and undergo symptomatic therapy: antacids, histamine H2 receptor blockers, proton pump inhibitors. Hemodialysis is ineffective.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf life

5 years.

Manufacturer

Bayer Bitterfeld GmbH, Germany